Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NVS: Novartis AG -- Ignore unavailable to you. Want to Upgrade?

To: Starlight who wrote (29)	5/10/2001 4:55:07 PM
From: Davy Crockett	Respond to of 116

Hi Elizabeth, some patients will get the drug free (depending on their income), others will qualify for assistance (I believe yearly income ABOVE $43,000-??), and others who can afford it will pay. I don't remember the details, but no one will be denied the drug if they can't afford to pay That's an amazing story, Peter

To: Starlight who wrote (29)	5/12/2001 10:12:13 PM
From: t2	Read Replies (2) \| Respond to of 116

This is an exciting story. The CEO of Novartis was on CNBC this afternoon. He mentioned that they are exploring treatment of other types of cancer using Gleevec, and that they are "very hopeful". I thought they have some other preliminary studies sometime this coming week. Since he said they are "very hopeful", one would have to think there is some promise in the trials they are currently carrying on. Of course, he can't say anything until the trial data has been analysed and released. This is my take on the way announced this approval by the FDA: The fact that NVS wants to help those earning less money in buying this new drug; makes me feel that this is not the end to their new treatments based upon this new approach. It is almost a hint that there is many possibilities in this company's future. What they announced last week may just be the beginning and they are just presenting it without making profits the number one concern for this company. If this was the end of the line, I doubt they would be making arrangements for those with less income. The reaction by the scientific community to this drug is incredible. I have not seen this much excitement for a drug launch in a long time. Just reading some of the comments from scientists in various articles tells how big this really is. Certainly, this is one stock that is going to outperform its peers. Now just over 40 is a bargain especially since the growth is expected to pick up next year. That April 23rd post on this message board is the reason for buying this stock. The company has a lot of promise and its growth is ahead of it. The other possibilities for this drug are noted in that article as well.